We may be starting a fire only to try putting it out with a water gun.
Managing skin toxicity matters. But how certain are we that our mitigation strategies are sufficient, and that the overall balance of benefits and harms remains favorable?
#ESMO26 #LungCancer #Amivantamab
8 浏览 · 1 赞 · 0 转发 · 0 回复
Improving prevention of moderate to severe dermatologic adverse events in EGFR-mutant advanced NSCLC treated with first-line (1L) subcutaneous (SC) amivantamab + lazertinib: First results from a new COCOON cohort
https://esmocongress.esmo.org- **标题 / Title：** A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
https://esmocongress.esmo.org- **标题 / Title：** A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
https://esmocongress.esmo.org来源：Raffaele Giusti · x.com